OraSure Technologies (NASDAQ:OSUR) Director Steven Kyle Boyd Acquires 25,000 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd purchased 25,000 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was bought at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the purchase, the director owned 113,462 shares of the company’s stock, valued at approximately $339,251.38. This represents a 28.26% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Steven Kyle Boyd also recently made the following trade(s):

• On Tuesday, May 12th, Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock. The shares were bought at an average cost of $2.98 per share, with a total value of $74,500.00.

OraSure Technologies Stock Down 3.0%

Shares of NASDAQ:OSUR traded down $0.09 during midday trading on Thursday, reaching $2.95. 868,088 shares of the company were exchanged, compared to its average volume of 535,873. The firm has a market cap of $203.11 million, a PE ratio of -2.84 and a beta of 0.89. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $3.82. The stock has a fifty day simple moving average of $3.06 and a two-hundred day simple moving average of $2.76.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The firm had revenue of $26.76 million during the quarter, compared to analyst estimates of $26.44 million. OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%.

Institutional Trading of OraSure Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Sei Investments Co. raised its holdings in OraSure Technologies by 126.9% during the first quarter. Sei Investments Co. now owns 417,958 shares of the medical instruments supplier’s stock worth $1,254,000 after acquiring an additional 233,732 shares in the last quarter. Yorkville Advisors Global LP acquired a new position in shares of OraSure Technologies during the 1st quarter worth approximately $1,905,000. IMC Chicago LLC bought a new stake in OraSure Technologies during the first quarter worth $71,000. Diversify Wealth Management LLC bought a new stake in shares of OraSure Technologies in the 1st quarter valued at about $36,000. Finally, Hsbc Holdings PLC raised its stake in OraSure Technologies by 4.6% in the first quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier’s stock valued at $421,000 after buying an additional 6,218 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.